Jeffrey Guss, MD is a psychiatrist, psychoanalyst, researcher and teacher with specializations in psychoanalytic therapy and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, published in Journal of Psychopharmacology, 2016.He currently a Lead Trainer with Fluence, with a focus on the integration of psychedelic therapy with psychoanalysis. He is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, and published on the integration of Acceptance and Commitment Therapy with psychedelic assisted therapy for MDD in Journal of Contextual and Behavioral Science. .